GLP-1 Pills Are Here: What Changed in 2026

A physician-led comparison of FDA-approved oral GLP-1 options and weekly injections, using current labels and trial evidence.

Orforglipron is now an FDA-approved oral option. Foundayo (orforglipron) was approved effective April 1, 2026. The practical question is no longer whether this pill will be approved, but how an approved daily tablet compares with weekly injections for an individual patient. That decision still depends on the labeled indication, contraindications, medical history, tolerability, access, and preferences.

Which oral GLP-1 options are FDA-approved?

Two FDA-approved oral options now sit behind the phrase "GLP-1 pill." Oral semaglutide for weight management is taken once daily on an empty stomach with specific timing around food and water. Foundayo (orforglipron) is a once-daily small-molecule GLP-1 receptor agonist tablet that the label allows with or without food. They are different medicines with different labels and should not be treated as interchangeable.

Foundayo (orforglipron) is an FDA-approved GLP-1 receptor agonist tablet taken once daily, with or without food. Its approval was effective April 1, 2026. The label indicates it with a reduced-calorie diet and increased physical activity for long-term weight reduction in adults with obesity, or with overweight and at least one weight-related condition. Trial averages describe the study population, not an individual result.

How do the pills compare to injections right now?

Cross-trial averages can help frame a conversation, but they cannot prove that one medicine or one format is better for an individual. Orforglipron produced about 12.4% average weight reduction at 72 weeks in its efficacy analysis. Injectable semaglutide averaged about 14.9% in STEP-1 and injectable tirzepatide about 20.9% in SURMOUNT-1. The drugs, trial populations, and designs differ, so results should not be ranked as if they came from one head-to-head trial.

For context on the injectables: in the STEP-1 trial, semaglutide produced an average of about 14.9% of body weight lost, and in SURMOUNT-1, tirzepatide averaged about 20.9%. Those are the FDA-approved brand products, semaglutide sold as Wegovy (Novo Nordisk) and tirzepatide sold as Zepbound (Eli Lilly), neither affiliated with this clinic. The injectables also carry outcome data the oral drugs do not yet have: the SELECT trial showed Wegovy cut major cardiovascular events by about 20% in people with established cardiovascular disease, and the SURMOUNT-OSA program led to Zepbound becoming the first medication FDA-approved for moderate-to-severe obstructive sleep apnea.

So today the comparison is roughly this. Pills offer convenience and needle-free dosing. Injections offer a longer track record and, on average, larger weight loss. That gap may narrow over time. It has not closed yet.

Why do some people still prefer a pill?

Preference is legitimate, and I do not talk patients out of theirs. Some people have a genuine, not-going-away fear of needles. Some travel constantly and do not want to manage refrigeration or sharps disposal. Some have tried an injectable and simply want a different daily rhythm. For those individuals, a once-daily tablet is not a lesser choice, it is the choice they will actually stick with, and adherence is what produces results.

What I ask people to be honest about is the reason. "I would rather swallow a pill" is a fine reason to plan around a pill. "I am waiting for the pill because I am not ready to start" is a different thing wearing the same clothes, and it deserves a more direct conversation.

Where do injections have a longer evidence record?

The injectable GLP-1 and dual-agonist therapies have years of peer-reviewed data behind them across weight, cardiovascular events, kidney outcomes, liver disease, and sleep apnea. The FLOW trial showed semaglutide reduced major kidney events by about 24% and death from any cause by about 20% in people with type 2 diabetes and chronic kidney disease. The ESSENCE trial supported FDA approval of Wegovy for a form of fatty liver with fibrosis in August 2025.

That depth of evidence can matter when a patient has a condition with a product-specific outcome indication. It does not make injections universally better, and it does not erase the approved evidence for oral treatment. A careful clinician should match each product's label and evidence to the patient's priorities, conditions, risks, and ability to follow the regimen. Compounded semaglutide and tirzepatide are not FDA-approved, not brand-identical, and individual results vary.

What should you compare before choosing?

Approval creates an option, not a universal answer. Compare the labeled indication, contraindications, dosing schedule, drug interactions, expected effects, risks, access, coverage, and your ability to follow the regimen.

Untreated obesity can carry costs, but starting a medicine that does not fit can also create avoidable problems. The useful decision is deliberate and individualized, based on the full medical picture rather than on pill versus injection alone.

Approval does not settle access, coverage, or whether a medicine is appropriate for a particular patient. Those details should be checked at the time of prescribing.

How should I make this decision with my doctor?

Bring the real question to the visit, not the headline. A useful conversation covers a few things:

• Your medical picture. Sleep apnea, cardiovascular disease, kidney disease, fatty liver, or diabetes may point toward a therapy that already has outcome data for your specific condition.
• Your honest tolerance for injections. If needles are a true barrier to starting or staying on treatment, that belongs in the plan now, not as an afterthought.
• Your goals and timeline. What are you hoping to change, and which dosing routine can you follow consistently?
• A switch-later option. Starting one approved therapy does not automatically prevent a later switch to another approved option. Any change requires a clinician to review the label, medical history, response, and tolerability.

At New Hope Weight Loss & Wellness, our consult is $119, and it is a real physician conversation, not a form. Compounded semaglutide runs $166 per month, about $5.50 a day, and compounded tirzepatide is $233 per month, about $7.70 a day, with 90-day Reset programs at $499 and $699. There is a one-month $199 Skeptics Trial for people who want to test the waters before committing. Everything is cash-pay, telehealth, bilingual, and HIPAA-private, with no insurance needed.

So how should you choose now?

The oral option is now here, so the decision is no longer simply start now or wait. It is whether an approved daily tablet or an approved injection better fits the patient's clinical needs and preferences. FDA approval does not make either format universally better, and results vary.

Frequently asked questions

This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.